Wells Fargo & Company Acumen Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 20,431 shares of ABOS stock, worth $48,830. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,431
Previous 1,208
1591.31%
Holding current value
$48,830
Previous $4,000
1125.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ABOS
# of Institutions
85Shares Held
41.9MCall Options Held
239KPut Options Held
65.9K-
Ra Capital Management, L.P. Boston, MA14.9MShares$35.7 Million0.54% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$8.17 Million4.16% of portfolio
-
Franklin Resources Inc San Mateo, CA3.37MShares$8.05 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$5.5 Million0.17% of portfolio
-
Black Rock Inc. New York, NY2.16MShares$5.16 Million0.0% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $96.8M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...